

Managing Outpatient Treatment of COVID-19: Impact of Continuing Education for Healthcare Professionals

Logan Van Ravenswaay, PharmD
Sarah L. Anderson, PharmD, BCACP, FASHP, FCCP
Zachary Schwartz, MSc, ELS

Background

- Since January 2022, 3 antiviral medications have been available for the treatment of nonhospitalized patients with COVID-19
- To stay current with the latest science, healthcare professionals (HCPs) must understand *patient risk stratification* and *appropriate antiviral selection* based on timing and patient-specific factors

Aim

Assess practice trends via survey among HCPs before and after participating in education targeted at improving their ability to employ COVID-19 antivirals according to guidelines

Educational Program Learners


More than 24,000 learners interacted with program content between September 2022 and November 2023

 **2276**
Live Learners

 **22,433**
Online Learners

Eligible for surveys 1 and 2


Survey Respondent Information




■ Presurvey (n = 285) ■ Survey 1 (n = 68) ■ Survey 2 (n = 37)

NP, nurse practitioner; PA, physician assistant


Education Timeline



Baseline Confidence Scores (N = 285)




Final Survey Data (N = 34)




Educational Program Impact

Positive Impact on Practice

Learners were asked, “Based on your participation in this activity, do you intend to change your practice behavior?”



Important Barriers Reported



Conclusions

- We observed varying levels of baseline confidence across the United States, with noted **posteducation improvements** in perceived learner ability to **risk stratify patients** and **select appropriate antivirals**
- As new COVID-19 treatment recommendations emerge, continuing education programs will be essential to provide targeted and timely interventions to address and prevent barriers to care

Supported by an educational grant from Gilead Sciences, Inc. and Merck Sharp & Dohme Corp.

